EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

HER2 Positive and Triple Negative Breast Cancer: A Review

Viola Vinita DSA, Amith M N, Umesh M, Charan C S, Hanumanthachar Joshi

International Journal of Community Pharmacy · 30.09.2024 · 53-60

DOI: 10.65301/ijcp.2024.5.3.8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Community Pharmacy, online erschienen am 30.09.2024. Verfasst von Viola Vinita DSA und 4 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Cancer is the most common cause of mortality and morbidity seen in all over the world. Breast cancer is the second most prevalent type of non-skin cancer and the fifth most common cause of cancer-related mortality worldwide, accounting for 10.4% of all cancer incidences among women. HER2 is a protein that plays a role in cell growth and differentiation accounts for 15-20% of HER2- Positive breast cancer. Lack of expression of Estrogen & Progesterone Receptor and the absence of human epidermal growth factor receptor 2 (HER2) and accounts for 15% of Triple negative breast cancer of all cases

Zitieren

APA

DSA, V. V., N, A. M., M, U., S, C. C., & Joshi, H. (2024). HER2 Positive and Triple Negative Breast Cancer: A Review. International Journal of Community Pharmacy, 53-60. https://doi.org/10.65301/ijcp.2024.5.3.8

Vancouver

DSA VV, N AM, M U, S CC, Joshi H. HER2 Positive and Triple Negative Breast Cancer: A Review. International Journal of Community Pharmacy. 2024:53-60. doi:10.65301/ijcp.2024.5.3.8

BibTeX
@article{DSA2024,
  author = {DSA, Viola Vinita and N, Amith M and M, Umesh and S, Charan C and Joshi, Hanumanthachar},
  title = {HER2 Positive and Triple Negative Breast Cancer: A Review},
  journal = {International Journal of Community Pharmacy},
  year = {2024},
  pages = {53--60},
  doi = {10.65301/ijcp.2024.5.3.8}
}
Kostenlos starten →